Why peptides are suddenly a 2026 category conversation
For most of the last two years, regenerative peptides like BPC-157 and TB-500 were a gray-market story.
That is changing in 2026.
On April 22, 2026, the FDA officially removed twelve peptides, including BPC-157, TB-500, KPV, MOTs-c, Semax, Epitalon, and DSIP, from its list of bulk drug substances that present significant safety risks under section 503A. On July 23 and 24, 2026, the Pharmacy Compounding Advisory Committee will meet at the FDA White Oak Campus to formally discuss whether several of these peptides should be added to the 503A Bulks List.
For telehealth operators, this is the most important regulatory shift in the wellness category since GLP-1s became mainstream. It is also one of the easiest stories to get wrong.
This post is not a clinical guide. It is an operating guide for telehealth teams that are watching the category and trying to figure out what to actually do before July.
What actually changed on April 22, 2026
The FDA updated its list of bulk drug substances that may present significant safety risks for use in compounding.
In plain language, the agency removed a number of peptides from the list that has effectively blocked them from routine 503A compounding for the last several years. The peptides removed from that list include:
- BPC-157 (free base and acetate)
- TB-500 (free base and acetate)
- KPV (free base and acetate)
- MOTs-c (free base and acetate)
- Semax (free base and acetate)
- Epitalon (free base and acetate)
- Emideltide, also known as DSIP
This is the first concrete regulatory step toward making these substances available again through licensed compounding pharmacies.
But removal from the safety-risk list does not, by itself, authorize compounding. It clears the way for the next step in the FDA process. That next step is the 503A Bulks List, and that is what the July committee meeting is about.
What the July 23-24 PCAC meeting actually decides
The Pharmacy Compounding Advisory Committee, or PCAC, is the FDA panel that reviews bulk drug substances proposed for the 503A Bulks List. Inclusion on the 503A Bulks List is what allows licensed pharmacists to legally compound a substance for an individual patient prescription under section 503A.
According to the FDA's published meeting notice, the agenda is:
- July 23, 2026: BPC-157, KPV, TB-500, and MOTs-c
- July 24, 2026: Emideltide (DSIP), Semax, and Epitalon
Public comments must be submitted to docket FDA-2025-N-6895 by July 9, 2026 to be presented to the committee.
Three things are worth understanding clearly.
First, PCAC is advisory. It votes and recommends. The FDA then makes the final decision, and that decision is published in a separate notice and ultimately codified in regulation. PCAC voting "yes" on a peptide does not, on its own, immediately make it legal to compound at scale.
Second, even if a peptide is added to the 503A Bulks List, it can only be compounded under a valid prescription for an individual patient by a licensed pharmacy following 503A conditions. Telehealth platforms will still need a clinician relationship, an individualized prescription, and a compounder that is set up to handle the substance.
Third, peptides not on the July agenda, including CJC-1295, Ipamorelin, Thymosin Alpha-1, AOD-9604, and Selank, are on a separate track. Several have been moved out of the safety-risk list and referred to PCAC for review at later meetings.
The realistic interpretation is this. July is a major step. It is not a switch that flips the category on.
Why "after July 2026, you can sell peptides" is not the right framing
A lot of category coverage is treating the July meeting as if it ends with peptides going on shelves through telemedicine platforms.
That is not how this works.
The Real 2026 Peptide Timeline
Removal from Category 2 is the first gate, not the last. The path from April 2026 to a legally compoundable peptide runs through the PCAC meeting, an FDA determination, and 503A Bulks List inclusion.
- 1April 22, 2026Complete
Removed from Category 2
BPC-157, TB-500, KPV, MOTs-c, Semax, Epitalon, and DSIP exit the FDA's significant-safety-concerns list. Compounding still not authorized.
- 2July 9, 2026Upcoming
Public comment deadline
Final day to submit comments to docket FDA-2025-N-6895. Comments after this date are not presented to the committee.
- 3July 23-24, 2026Upcoming
PCAC meeting at White Oak
Pharmacy Compounding Advisory Committee reviews and votes on adding peptides to the 503A Bulks List. Day 1 covers BPC-157, KPV, TB-500, MOTs-c. Day 2 covers DSIP, Semax, Epitalon.
- 4Post-meetingPending FDA
FDA determination
FDA reviews the PCAC recommendations and publishes a determination, typically through a notice or proposed rule. Usually months, not days.
- 5503A Bulks ListPending FDA
Compounding becomes legal
Once a peptide is formally included, licensed 503A pharmacies may compound for individual patients with a valid prescription, subject to the rest of the framework.
The platforms that will actually be ready to operate in this category are not the ones treating July as a launch date. They are the ones using the runway between now and the FDA's formal action to build the underlying operating model.
What telehealth teams should be doing now
If you are building a telehealth program that may include peptides in the next twelve to eighteen months, this is the work that compounds value before the regulatory door opens.
1. Decide which peptides are part of your roadmap, and why
Not every peptide on the July agenda fits every program. The realistic groupings are:
- Tissue and gut recovery: BPC-157, TB-500, KPV
- Metabolic and longevity: MOTs-c, Epitalon
- Neurocognitive: Semax, DSIP
- Growth hormone secretagogues, on a separate track: CJC-1295, Ipamorelin
Pick the subset that fits your existing clinical model and your existing patient base. A weight management program is more naturally adjacent to MOTs-c and the GH secretagogues. A men's health or recovery program is more naturally adjacent to BPC-157 and TB-500. Trying to launch all of them at once is the fastest way to make the program look like a supplement catalog rather than a clinical service.
2. Tighten your pharmacy strategy before the supply question matters
Compounding pharmacy quality is the single biggest operational risk in this category.
Pharmacies that will be set up to handle peptides cleanly under 503A need:
- USP-grade or pharmacopeia-grade peptide raw materials
- documented sourcing and certificates of analysis
- proper sterile compounding workflow for injectables
- validated stability and beyond-use dating
- a real, documented relationship with prescribers, not a fulfillment-only posture
If your current compounding partner is mostly running semaglutide and tirzepatide volume, they may or may not be the right partner for peptides. This is the right time to evaluate. For a starting framework, see How to Choose a Compounding Pharmacy for Your Telehealth Program.
3. Design intake and clinical review for individualized prescriptions
503A compounding is built around the individual prescription. That has real implications for intake design.
A peptide intake cannot look like a supplement quiz. It needs to:
- collect a real medical history
- screen for contraindications and concurrent therapies
- document the indication and goals in a way a clinician can actually act on
- support a synchronous or asynchronous clinical visit, depending on state requirements
If your current intake was built for a single GLP-1 funnel, plan for at least one full redesign cycle for peptides. For the underlying mechanics, see Design Research for Intake Forms in GLP-1 Telehealth and Weight Loss Intake Form Scorecard.
4. Build a marketing posture you can defend
This is where most early peptide programs will trip.
The realistic compliance posture for the next six to twelve months is:
- no claims that peptides are FDA-approved drugs, because they are not
- no implicit or explicit promises of specific therapeutic outcomes
- no language that treats compounded peptides as equivalent to approved products
- no marketing that runs ahead of the actual regulatory status of a given substance
If your existing GLP-1 marketing already runs into off-label or shortage-era talking points, peptides will magnify that risk, not reduce it. Pair this with Running GLP-1 Ads in 2026.
5. Plan billing and refill UX before launch, not after
Peptides will mostly be self-pay. The patient experience around price, cycle length, and reorder timing has to be clear from day one, because there is no insurance backstop to absorb confusion.
Operators that have already invested in clean billing and refill UX for GLP-1s will have a lighter lift. Those that have not should treat peptides as a forcing function. For the underlying patterns, see Billing UX for Telehealth and GLP-1 Refill Operations Workflow.
What to watch between now and July
Between April 28 and July 23, the most important signals for telehealth operators are:
- Public comments filed in docket FDA-2025-N-6895
- Statements from FDA leadership about the agency's posture on peptide compounding
- Any updates from the Outsourcing Facility (503B) side of the market, which is on a separate track
- Counterfeit and adulteration enforcement activity, which usually accelerates around regulatory transitions
- State pharmacy board guidance, which often moves faster than the FDA on practical day-to-day rules
The teams that operate well in this category in 2027 will be the teams that use the next ninety days to build the program, not the teams that wait for the meeting to happen and then start scoping.
Final takeaway
The April 22 removal and the July 23-24 PCAC meeting together represent the most credible regulatory opening for compounded regenerative peptides in years. They are not, on their own, a green light for a launch. They are a gating event that telehealth teams should plan around carefully.
The operating opportunity is for platforms that treat this like a real clinical category, with proper intake, proper compounding partners, proper clinician review, and disciplined marketing. That is what will separate the programs that scale from the programs that get a warning letter.
If peptides are on your 2026 or 2027 roadmap, continue with our companion piece, Building a Peptide Therapy Program: A Practical Map of BPC-157, TB-500, MOTs-c, and the 2026 Pipeline, and tie the operating layer to How to Launch a GLP-1 Telehealth Program.